scholarly journals CardioPulse Articles * The National Cardiac Societies of the European Society of Cardiology * Cardiology update 2015: a tradition in excellent postgraduate education supported by the European Society of Cardiology * Sir Donald Ross, pioneer aortic valve surgeon * Plans of the British Cardiovascular Society to seek patients' views on research may aid research grant applications * Dr Hector Bueno reviews the proposed criteria of the German Society of Cardiology for the Establishment of Chest Pain Units1 in their 2014 update * People's corner: Frank Enseleit MD FESC * Frank Enseleit joins the EHJ editorial team as a new Local Associate Editor

2015 ◽  
Vol 36 (21) ◽  
pp. 1278-1283
Keyword(s):  
Chest Pain ◽  
Aortic Valve ◽  
European Society ◽  
Postgraduate Education ◽  
German Society ◽  
Associate Editor ◽  
Editorial Team ◽  
Grant Applications ◽  
European Society Of Cardiology ◽  
Research Grant

scholarly journals Impact of more conservative European Society of Cardiology guidelines on the management of patients with acute chest pain

2021 ◽  
Author(s):  
Calvin L. Kienbacher ◽  
Verena Fuhrmann ◽  
Raphael Tulder ◽  
Christof Havel ◽  
Wolfgang Schreiber ◽  
...  
Keyword(s):  
Chest Pain ◽  
European Society ◽  
Acute Chest Pain ◽  
European Society Of Cardiology

scholarly journals Effectiveness and Safety of the European Society of Cardiology 0-/1-h Troponin Rule-Out Protocol: The Design of the ESC-TROP Multicenter Implementation Study

Cardiology ◽  
2020 ◽  
Vol 145 (11) ◽  
pp. 685-692
Author(s):  
Arash Mokhtari ◽  
Ardavan Khoshnood ◽  
Jakob Lundager Forberg ◽  
Caroline Hård af Segerstad ◽  
Ulf Ekström ◽  
...  
Keyword(s):  
Chest Pain ◽  
Clinical Assessment ◽  
European Society ◽  
Troponin T ◽  
High Sensitivity ◽  
Routine Care ◽  
Coronary Syndrome ◽  
European Society Of Cardiology ◽  
Pain Patients ◽  
Rule Out

Chest pain is one of the most common complaints at the emergency department (ED), and it is commonly the perceived likelihood of acute coronary syndrome (ACS) that drives management. Guidelines from the European Society of Cardiology (ESC) recommend the use of a 0-/1-h high-sensitivity cardiac troponin T (hs-cTnT) protocol to rule out or in ACS, but this is mostly based on observational studies. The aim of the ESC-TROP trial is to determine the safety and effectiveness of the ESC 0-/1-h hs-cTnT protocol when implemented in routine care. Adult chest pain patients at 5 EDs in the Skåne Region, Sweden, are included in the trial. The 0-/1-h hs-cTnT ESC protocol supplemented with clinical assessment and electrocardiography (ECG) is implemented at 3 EDs, and the other 2 EDs act as concurrent controls. Outcomes will be evaluated during the 10 months after the implementation and the corresponding 10 months of the previous year. The 2 co-primary outcomes are (a) acute myocardial infarction (AMI) and all-cause death within 30 days in patients discharged from the ED, and (b) ED length of stay of the same patients. Secondary outcomes include the proportion of chest pain patients discharged from the ED and the number of ruled-out patients undergoing objective testing within 30 days. The ESC-TROP trial will determine the performance and applicability of the 0-/1-h hs-cTnT ESC protocol supplemented with clinical assessment and ECG when implemented in routine ED care. It will provide evidence whether 0-/1-h hs-cTnT testing is safe, effective, and feasible, and whether widespread implementation as recommended by ESC guidelines should be supported.

Implementing the European Society of Cardiology 0-h/1-h algorithm in patients presenting very early after chest pain

2020 ◽  
Vol 320 ◽  
pp. 1-6
Author(s):  
Masayuki Shiozaki ◽  
Kenji Inoue ◽  
Satoru Suwa ◽  
Chien-Chang Lee ◽  
Shuo-Ju Chiang ◽  
...  
Keyword(s):  
Chest Pain ◽  
European Society ◽  
European Society Of Cardiology

scholarly journals Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre

2021 ◽  
Vol 2021 (3) ◽  
Author(s):  
Ioanna Istampoulouoglou ◽  
Georgios Dimitriou ◽  
Selina Späni ◽  
Andreas Christ ◽  
Barbara Zimmermanns ◽  
...  
Keyword(s):  
Chest Pain ◽  
Length Of Stay ◽  
Adverse Events ◽  
European Society ◽  
Vaccine Dose ◽  
Acute Chest Pain ◽  
Pharmacovigilance Centre ◽  
Median Length ◽  
Median Latency ◽  
European Society Of Cardiology

In this article we summarize suspected adverse events following immunization (AEFI) of pericarditis, myocarditis and perimyocarditis that were reported by our regional pharmacovigilance centre after COVID-19 mRNA-vaccination and discuss their association with these vaccines. Seventeen cases were reported between March and July 2021. Of these, nine had perimyocarditis, five myocarditis and three pericarditis. Twelve patients were male (71 %). The median age was 38 years (range 17 - 88). The most commonly observed presenting symptom was acute chest pain (65%). While 47% of the patients were previously healthy, 53% had at least one pre-existing comorbidity, with hypertension being the most prevalent (24%). The European Society of Cardiology diagnostic criteria for the reported AEFIs were fulfilled in twelve cases (71%). The AEFIs occurred after the first vaccine dose in six cases (35%), after the second vaccine dose in ten cases (59%) and after both doses in one case (6%). The median latency of all AEFIs taken together was 14 days (range 1 - 28) after the first vaccination and 3 days (range 1 - 17) after the second one. All patients except one were hospitalized (94%) with a median length of stay of 7.5 days (range 3 - 13). The majority of patients (n = 11, 65%) did not experience any complications, and 13 (77%) of the patients were recovered or recovering at the time of discharge. In 16 of the 17 cases (94%), the association between the AEFI and mRNA-vaccination was considered possible by the pharmacovigilance centre.

scholarly journals Risk determination, diagnosis and prevention of cardiotoxicity with chemotherapeutic medications and radiation therapy Guidelines of the Ukrainian Association of Cardiology

2021 ◽  
Vol 27 (6) ◽  
pp. 71-81
Author(s):  
V. M. Kovalenko ◽  
E. G. Nesukay
Keyword(s):  
Radiation Therapy ◽  
European Society ◽  
Medical Oncology ◽  
Postgraduate Education ◽  
Chemotherapeutic Drugs ◽  
Cardiovascular Toxicity ◽  
Patients With Cancer ◽  
Therapy Guidelines ◽  
European Society Of Cardiology ◽  
Higher Medical Education

The recommendations were developed by the Ukrainian Association of Cardiology based on the expert opinion and recommendation documents of the Heart Failure Association, the European Association of Cardiovascular Imaging (EACVI), the Cardiooncology Committee of the European Society of Cardiology (ESC), European Society for Medical Oncology (ESMO), American Echocardiographic Society. They focus on risk assessment, diagnostic and prophylactic approaches to reduce cardiovascular toxicity due to the use of chemotherapeutic drugs and radiation therapy in patients with cancer. Intended for cardiologists, therapists, family physicians, oncologists, researchers, teachers of higher medical education and postgraduate education.

Sign in / Sign up

Export Citation Format

Share Document